Navigation Links
Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress
Date:5/26/2011

FORT LEE, N.J., May 26, 2011 /PRNewswire/ -- Neurologix, Inc. (OTCBB: NRGX) announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD).  Improvements in the Unified Parkinson's Disease Rating Scale (UPDRS) at 12 months for the randomized, double-blind, sham surgery-controlled trial of 45 subjects with advanced PD confirmed that patients treated with NLX-P101 experienced sustained, positive, long-term benefits. The one-year follow-up data were presented by one of the scientific co-founders of Neurologix, Michael G. Kaplitt, M.D., Ph.D., at the International Neuromodulation Society's (INS) 10th World Congress in London.

In the one-year follow-up analysis, patients treated with NLX-P101 who achieved previously defined moderate-to-large clinically-meaningful symptom improvements (> / = 9 points in off-medication UPDRS motor score), increased from 50 percent at six months to 63 percent at one year. This major subgroup of NLX-P101-treated patients experienced a mean 37 percent improvement in their symptoms after one-year, with an average improvement of 14 points in off-medication UPDRS motor score. Among all patients included in the NLX-P101 treatment group, the clinical improvements demonstrated at six months were maintained, with an average 8.2 point improvement in off-medication UPDRS motor score at 12 months compared to an 8.1 point improvement at six months. No serious adverse events (SAEs) related to the gene therapy or surgical procedure were reported in either the blinded six-month study period or the completed 12 month study phase.

"These results demonstrate that treatment with NLX-P101 improved the primary motor symptoms of Parkinson's disease in patients overall, with a majority obtaining a highly clinically meaningful improvement," said
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
2. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
3. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. GeoVax Presents Data at AIDS Vaccine 2008 Conference
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
9. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
11. AmeriCares Presents Power of Partnership Award to Baxter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)...   SunTrust Robinson Humphrey (STRH) today ... its equity research team in biotechnology and oilfield ... equity research demonstrates our commitment to providing our ... their investment decision making," said Biff Woodruff ... to make significant investments in differentiated content at ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... - Listed companies to present at Therapeutic ... 2 Elsevier Business Intelligence and Windhover ... list. The list delivers projects and companies with high-value assets for ... in deals. This year,s list includes a Top 10 ...
... significantly improve the efficiency at which gallium nitride ... The devices are believed to be the first ... creation of an electrical charge in a piezoelectric ... mechanical strain to the microwires, researchers at the ...
... Oct. 31, 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2011. For the third quarter of 2011, ... fully diluted share outstanding, compared to net income of $3.3 million, ... in 2010. For the nine months ended September 30, 2011, the ...
Cached Biology Technology:Windhover Announces the "Top Biopharma Projects to Watch" 2Windhover Announces the "Top Biopharma Projects to Watch" 3Zinc oxide microwires improve the performance of light-emitting diodes 2Zinc oxide microwires improve the performance of light-emitting diodes 3Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... that corals whose calcium-carbonate skeletons form the ... that rely entirely on ocean currents to deliver ... now scientists at MIT and the Weizmann Institute ... they are far from passive, engineering their environment ... enhance their ability to exchange nutrients and dissolved ...
(Date:9/1/2014)... It may be possible to train the brain ... according to new research by scientists at the Jean ... HNRCA) at Tufts University and at Massachusetts General Hospital. ... Diabetes , a brain scan study in adult men ... the addictive power of unhealthy food while also increasing ...
Breaking Biology News(10 mins):Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Nature's tiny engineers 2Nature's tiny engineers 3Training your brain to prefer healthy foods 2
... forces laboratory leukemia cells to commit cell suicide, according ... that within 24 hours, 76 percent of leukemia cells ... The investigators, who report their findings in the January ... a journal of the American Association for Cancer Research, ...
... who took beta carotene or vitamin C or E or ... cancer as women who did not take the supplements, according ... 30 online issue of the Journal of the National ... whose diets are high in fruits and vegetables, and thus ...
... new clinical trial suggests that long-term use of candesartan, ... reduce the symptoms of genetic heart disease. The ... candesartan on left ventricular hypertrophy and function in non-obstructive ... January issue of The Journal of Molecular Diagnostics ...
Cached Biology News:Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds 2Vitamins C and E and beta carotene again fail to reduce cancer risk in randomized controlled trial 2
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... Mch3 Lyophilized solid. Highly ... and kinetics, cleavage of target substrates, and inhibitor screening. ... One unit is defined as the amount of ... No. 235400 per hour at 37 C at saturated ...
Biology Products: